Physician profile
Vahe Akopian
NPI 1649519588
$24,721.14
in general payments reported to CMS, 2019-2025
77 companies · $3,985 in 2025
The $3,985 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,994 · 2020: $2,674 · 2021: $3,872 · 2022: $3,865 · 2023: $3,601 · 2024: $4,730 · 2025: $3,985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,005.51 |
| Education | $310.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,606.30 | 2020-2025 | Ubrelvy, Botox, Qulipta |
| Ucb, INC. | $1,434.38 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Livanova USA, INC. | $1,400.43 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Celgene Corporation | $1,390.99 | 2021-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $1,220.42 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,202.39 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sk Life Science, INC. | $1,033.31 | 2020-2025 | Xcopri |
| Biogen, INC. | $983.93 | 2019-2025 | Vumerity, Tysabri |
| Emd Serono, INC. | $976.01 | 2019-2025 | Mavenclad, Mavenclad |
| Amgen INC. | $950.77 | 2019-2025 | Uplizna |
| Lundbeck LLC | $763.58 | 2021-2025 | Vyepti, Rexulti |
| Acadia Pharmaceuticals INC | $689.67 | 2019-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $662.14 | 2019-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $655.24 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Pfizer INC. | $577.30 | 2019-2025 |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vahe Akopian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.